PD-L1 Blocking Peptide peptide (STJ505468)

SKU:
STJ505468-250

Shipping:
Free Shipping
Current Stock:
Applications: Immunodepletion/Immunocompetition
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: PD-L1 Blocking Peptide is synthetically produced from the 80-130 sequence and is suitable for use in western blot applications.
Formulation: Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: CD274
Gene ID: 29126
Uniprot ID: PD1L1_HUMAN
Immunogen Region: 80-130
Immunogen: Synthetic peptide taken within amino acid reigon 80-130 on human Progammed cell death 1 ligand 1 protein.
Tissue Specificity Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. Isoform 4: Widely expressed, highest in lung, liver and pituitary and in various peripheral blood cells, including neutrophils and some subtypes of lymphoid and myeloid cells.
Post Translational Modifications Ubiquitinated.STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8.leading to degradation.
Function Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
Peptide Name Programmed Cell Death 1 Ligand 1
Pd-L1
Pdcd1 Ligand 1
Programmed Death Ligand 1
Hpd-L1
B7 Homolog 1
B7-H1
Cd Antigen Cd274
Database Links Reactome: R-HSA-389948
Reactome: R-HSA-9701898
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Early Endosome Membrane
Recycling Endosome Membrane
Nucleus
Associates With Cmtm6 At Recycling Endosomes
Where It Is Protected From Being Targeted For Lysosomal Degradation
Translocates To The Nucleus In Response To Hypoxia Via Its Interaction With Phosphorylated Stat3
Isoform 1: Cell Membrane
Isoform 2: Endomembrane System
Isoform 4: Secreted
Alternative Peptide Names Programmed Cell Death 1 Ligand 1 protein
Pd-L1 protein
Pdcd1 Ligand 1 protein
Programmed Death Ligand 1 protein
Hpd-L1 protein
B7 Homolog 1 protein
B7-H1 protein
Cd Antigen Cd274 protein
CD274 protein
B7H1 protein
PDCD1L1 protein
PDCD1LG1 protein
PDL1 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance